How Does Symdeko Work? Mechanism of Action Explained in Plain English

To understand how Symdeko works, it helps to first understand what goes wrong in cystic fibrosis (CF) at the molecular level — and then see how Symdeko's two active ingredients address those specific problems. No biochemistry degree required.

What Causes Cystic Fibrosis?

CF is caused by mutations in the CFTR gene — the genetic instructions for building a protein called the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is a channel protein that sits on the surface of cells lining the lungs, intestines, pancreas, and other organs. Its job is to control the flow of chloride (salt) and water in and out of cells.

When the CFTR gene has mutations, the protein is either missing, misfolded, or fails to function properly. The result: chloride can't move normally across cell membranes. This disrupts the water balance on cell surfaces, leading to thick, sticky mucus that builds up in the lungs, blocks ducts in the pancreas, and causes serious problems throughout the body.

The F508del Problem: A Protein That Gets Lost

The most common CF mutation is called F508del (or Phe508del). This mutation causes the CFTR protein to be misfolded — it can't take on the correct three-dimensional shape needed to reach the cell surface. Instead, the misfolded protein gets flagged by the cell's quality control system and destroyed before it can ever do its job.

Even if a small amount of F508del CFTR does reach the cell surface, it doesn't work properly — the channel doesn't open long enough or often enough to allow chloride to flow through.

This is a two-pronged problem:

Processing defect: The protein doesn't fold properly and can't get to the cell surface.

Gating defect: The protein, if it does reach the surface, doesn't stay open long enough for chloride to flow.

How Tezacaftor (the Corrector) Addresses the Processing Defect

Tezacaftor is a CFTR corrector. Think of it as a molecular chaperone or folding guide for the CFTR protein.

When CFTR protein is produced from the mutated gene, tezacaftor binds to it and helps it fold into its correct three-dimensional shape. With the right shape, the protein can pass through the cell's quality control process, travel to the cell surface, and actually get into position where it can function as a chloride channel.

Tezacaftor doesn't fix the CFTR gene itself — the mutation is still there. Instead, it acts as a helper that compensates for the folding problem caused by the mutation, allowing more of the CFTR protein to successfully reach the cell surface.

How Ivacaftor (the Potentiator) Addresses the Gating Defect

Ivacaftor is a CFTR potentiator. Think of it as a doorstop that keeps the chloride channel open.

Once CFTR protein has been corrected by tezacaftor and has reached the cell surface, ivacaftor binds to it at the surface and helps keep the channel gate open. This allows chloride to flow more freely through the channel — which is exactly what the normal CFTR protein is supposed to do.

Ivacaftor (also sold as Kalydeco) was the first CFTR modulator approved by the FDA, back in 2012. On its own, it works for patients with certain "gating" mutations where the protein reaches the cell surface but doesn't function properly. For patients with F508del, the primary problem is getting the protein to the surface at all — so ivacaftor alone isn't enough. That's why combining it with tezacaftor in Symdeko is necessary.

Why Trikafta Is Even More Effective

Trikafta (elexacaftor/tezacaftor/ivacaftor) adds a third ingredient: elexacaftor, which is a next-generation corrector that works at a different point in the CFTR folding process than tezacaftor. By attacking the processing defect from two different angles — plus keeping the channel open with ivacaftor — Trikafta gets significantly more functional CFTR protein to the cell surface, leading to greater clinical benefit.

This is why Symdeko's mechanism — though effective — is considered a stepping stone to the triple-combination approach of Trikafta and Alyftrek, which are more effective for most eligible patients.

What Symdeko Actually Does in the Body

When Symdeko works as intended:

More functional CFTR protein reaches the surface of airway cells

Chloride and water balance improves across cell surfaces

Mucus becomes less thick and sticky

Lung function improves (measured as an increase in ppFEV1)

Risk of pulmonary exacerbations (acute episodes of worsening) decreases

Quality of life and respiratory symptoms improve

Does Symdeko Work for Everyone with CF?

No. Symdeko only works for patients whose CFTR mutations produce some CFTR protein that can be corrected and potentiated. Patients with certain mutations that result in no CFTR protein being made at all (called "minimal function" mutations) do not benefit from tezacaftor alone. However, these patients may benefit from Trikafta or Alyftrek, which address a broader range of mutation types.

For more details on who Symdeko is approved for, see: What Is Symdeko? Uses, Dosage, and What You Need to Know in 2026.

Need help finding your Symdeko prescription? medfinder calls pharmacies on your behalf to find which ones can fill it.